Remote-Controlled Synthetic Cells Offer Breakthrough in PrecisRemote-Controlled Synthetic Cells Offer Breakthrough in Precision Cancer Therapyion Cancer Therapy

Researchers from University College London (UCL) and the University of Oxford have developed remote-controlled synthetic cells capable of delivering therapeutic proteins directly within the body. These engineered cells can be activated by an alternating magnetic field, effectively turning them into localized “drug factories” that release treatment molecules on demand.

The synthetic cells have undergone preliminary human safety assessments, demonstrating that they can operate safely in vivo. By enabling precise spatial and temporal control over drug release, this technology has the potential to significantly improve the efficacy of cancer treatments while minimizing systemic side effects, a major limitation of conventional therapies.

Photo by Diane Serik onUnsplash

Mechanism and Innovation

The cells remain inert until externally activated by a magnetic field, which triggers the release of therapeutic proteins at the tumor site. This approach integrates synthetic biology, nanotechnology, and precision medicine to create a fully controllable cellular therapy platform. Researchers believe this strategy could also be adapted for other diseases requiring localized treatment, such as autoimmune disorders or targeted gene therapies.

Clinical and Industry Implications

Current cancer treatments, including chemotherapy, CAR-T cell therapy, and gene therapies, often face challenges related to off-target toxicity, high costs, and limited patient accessibility. Remotely controlled synthetic cells could overcome several of these barriers, offering:

Enhanced safety: Reduced systemic exposure lowers the risk of adverse effects.

Targeted delivery: Drugs are released specifically at diseased tissue sites.

Flexible control: Physicians can adjust therapy timing and dosage non-invasively.

This innovation also highlights the critical role of Contract Development and Manufacturing Organizations (CDMOs) in supporting advanced therapies. CDMOs provide specialized expertise and infrastructure to manufacture complex cell and gene therapy products efficiently, ensuring that innovative treatments can reach patients safely and at scale.

Photo by Brano on Unsplash

Future Directions

While early results are promising, extensive clinical trials will be needed to evaluate long-term efficacy, safety, and scalability. Integration with existing immunotherapies may create combination strategies with synergistic effects, potentially improving outcomes for patients with solid tumors or metastatic cancers.

Source:

University College London, Synthetic cells could be a new way to deliver drugs inside the body, September 2025